Cambridge Healthcare Research, a Cambridge-based life sciences and healthcare consultancy, has named Stella Wooder as strategic adviser, it was reported yesterday.
Wooder has more than 25 years of experience of healthcare and technology consulting and she currently chairs the board of trustees at Team – which works with many large pharmaceutical and medical device companies to design and develop medical devices – after spending time delivering client projects at the consultancy through a significant phase of growth. She is also a non-executive director of Gynii Me – an early-stage company in the fertility treatment sector – and is an honorary lecturer at the Institute of Biotechnology at the University of Cambridge. Wooder's career has also included the role of operations director at science, technology and product development company Sagentia – where she worked for more than a decade – as well as time at life sciences consultancy, Pope Woodhead & Associates.
Edward Cartwright, a partner at CHR, said, 'We are delighted to welcome Stella to the team as we begin this new chapter in our growing success story. Her expertise in building successful healthcare consulting firms will be invaluable as we expand our global business to help even more healthcare clients, as well as product and brand teams, make sense of their rapidly evolving markets and inform their winning strategy.'
Zydus enters exclusive talks to acquire majority stake in Amplitude Surgical
Adcendo's ADCE-T02 Phase I study IND application receives US FDA approval
WHO grants Actinogen Medical's Xanamem/UE2343 non-proprietary name 'emestedastat'
IVFMD physicians named 2025 Castle Connolly Top Doctors
HOPE Therapeutics and NRx Pharmaceuticals select BTIG as financial advisor
Partillion Bioscience opens pre-orders for Nanovial Multicell Assay Antibody Discovery Kits
Champions Oncology expands bioanalytical services with new technology
Petauri's Nicole Lodowski named to MM+M's 40 Under 40 for 2025
WuXi XDC Cayman wins 'Best CDMO' at World ADC Awards 2024
Nektar Therapeutics agrees sale of Huntsville manufacturing facility and reagent supply business